世界の注入型ドラッグデリバリー（薬物送達）市場...市場調査レポートについてご紹介

Table Of Contents

1 Introduction (Page No. – 26)
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary (Page No. – 34)

3 Market Overview (Page No. – 39)
3.1 Introduction
3.2 Market Segmentation
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Technological Advancements
3.3.1.2 Favorable Reimbursement Environment To Bolster The Demand Of Self Injection Devices
3.3.1.3 Surge Of Biologics In European Pharmaceutical Market
3.3.1.4 Rising Incidences Of Cancer And Diabetes
3.3.1.5 Improving Patient Compliance
3.3.2 Restraints
3.3.2.1 Needle-Stick Injuries And Infections
3.3.2.2 Threat From Alternate Drug Delivery Methods
3.3.2.3 Slow Approval Process Of Drugs And Medical Devices In Europe
3.3.3 Opportunities
3.3.3.1 Development Of Biosimilars In The European Pharmaceutical Market
3.3.3.2 Need For Better Healthcare For The Increasing Geriatric Population Of Europe
3.3.4 Challenges
3.3.4.1 Sustainability Of Players In Highly Competitive Market
3.4 Market Share Analysis, By Major Players
3.4.1 Conventional Injectable Drug Delivery Devices
3.4.2 Self-Injection Devices-Pen Injectors

4 European Injectable Drug Delivery Devices Technologies Market (Page No. – 65)
4.1 Introduction
4.2 Market Segmentation
4.3 Manufacturers Criteria For Selection Of An Injectable Device
4.4 Conventional Injectable Drug Delvery Devices
4.4.1 By Usability
4.4.1.1 Disposable
4.4.1.2 Reusable
4.4.2 By Material
4.4.2.1 Glass
4.4.2.2 Plastic
4.4.3 By Product
4.4.3.1 Fillable
4.4.3.2 Prefilled
4.5 Self-Injection Devices
4.5.1 Market Segmentation
4.5.2 Selection Criteria For Self-Injection Device
4.5.3 Pen Injectors
4.5.3.1 By Product
4.5.3.1.1 Single Chamber Pen Injectors
4.5.3.1.2 Dual Chamber Pen Injectors
4.5.3.2 By Usability
4.5.3.2.1 Disposable Pen Injectors
4.5.3.2.2 Reusable Pen Injectors
4.5.3.3 By Design
4.5.3.3.1 Standard Pen Injectors
4.5.3.3.2 Customized Pen Injectors
4.5.4 Needle-Free Injectors
4.5.4.1 By Product
4.5.4.1.1 Prefilled Needle Free Injectors
4.5.4.1.2 Fillable Needle Free Injectors
4.5.4.2 By Technology
4.5.4.2.1 Jet-Based Needle-Free Injectors
4.5.4.2.2 Spring-Based Needle-Free Injectors
4.5.4.2.3 Laser-Based Needle Free Injectors
4.5.4.2.4 Vibration-Based Needle Free Injectors
4.5.4.3 By Usability
4.5.4.3.1 Disposable
4.5.4.3.2 Reusable
4.5.5 Auto Injectors
4.5.5.1 By Product
4.5.5.1.1 Prefilled Auto Injectors
4.5.5.1.2 Fillable Auto Injectors
4.5.5.2 By Technology
4.5.5.2.1 Automated Auto Injectors
4.5.5.2.2 Manual Auto Injectors
4.5.5.3 By Design
4.5.5.3.1 Standardized Auto Injectors
4.5.5.3.2 Customized Auto Injectors
4.5.5.4 By Usability
4.5.5.4.1 Disposable Auto Injectors
4.5.5.4.2 Reusable Auto Injectors
4.6 Others

5 European Injectable Drug Delivery Formulation Technologies Market (Page No. – 141)
5.1 Introduction
5.2 Conventional Drug Delivery
5.2.1 Injectable Solutions
5.2.2 Reconstituted/Lyophilized Formulations
5.3 Novel Drug Delivery Formulation Technologies
5.3.1 Market Segmentation
5.3.2 Liposomal Systems
5.3.3 Microspheres
5.3.4 Nanoparticles
5.3.5 Polymeric Micelles
5.3.6 Others

6 European Injectable Drug Delivery Technologies Market, By Therapeutic Applications (Page No. – 168)
6.1 Introduction
6.2 Auto-Immune Diseases
6.2.1 Multiple Sclerosis
6.2.2 Rheumatoid Arthritis
6.2.3 Crohn’s Diseases
6.2.4 Psoriasis
6.2.5 Others
6.3 Hormonal Disorders
6.3.1 Diabetes
6.3.2 Anemia
6.3.3 Reproductive Health Diseases
6.3.4 Antithrombotic/Thrombolytic Therapy
6.3.5 Osteoporosis
6.3.6 Growth Hormone Deficiency
6.4 Orphan/Rare Diseases
6.5 Oncology
6.6 Others
6.6.1 Pain Management
6.6.2 Hepatitis C
6.6.3 Allergies
6.6.4 Aesthetic Treatment

7 Geographic Analysis (Page No. – 215)
7.1 Introduction
7.2 Germany
7.2.1 More Than 25 New Medicines Are Due For Marketing License In Germany For The Year 2013
7.3 France
7.3.1 Higher Insurance Coverage, Increase In Aging Population And Affordability Drives The Market In France
7.4 U.K.
7.4.1 Highest Turnover Of Antibiotics And Small Molecules Due To Oncology And Infections
7.4.2 Bioscience & Health Technology Database Provide Better Industry Data On Injectable Technologies
7.5 Spain
7.5.1 Spain Is Amongst The Top 10 Countries With Highest Expenditure On Diabetes
7.6 Italy
7.6.1 Removal Of Linkages Between Patent And Generic Medicines Causes Rapid Access To Generics In Italy
7.7 Russia
7.7.1 Russian Government Aimed To Foster The Development Of Healthcare System
7.8 Rest Of Europe
7.8.1 Switzerland Has The Most Competitive Economy And Has Leading Position In Global Pharmaceuticals And Biotech Industries
7.8.2 Denmark Provides For Concentrated Patient Pool Especially For Diabetes Due To Centralization Of Healthcare System
7.8.3 High Acceptability For New Technologies And Lowest Corporate Tax Rate Drives The Ireland Market
7.8.4 Favorable Growth In Regions Of Portugal, Poland, And Romania Due To Increasing Diabetes Incidence And Related Reimbursement Policies

8 Competitive Landscape (Page No. – 251)
8.1 Introduction
8.2 Expansion
8.3 Agreements, Partnerships, Collaborations & Joint Ventures
8.4 New Product Launch
8.5 Mergers & Acquisitions
8.6 Other Developments

9 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)* (Page No. – 277)
9.1 Alkermes, Inc.
9.2 Bespak Europe, Ltd. (Subsidiary Of Consort Medical, Plc)
9.3 Crossject
9.4 Gerresheimer AG
9.5 Haselmeier Gmbh
9.6 Injex Pharma Gmbh (Subsidiary Of Hns International, Inc.)
9.7 Novo Nordisk A/S
9.8 Owen Mumford, Ltd.
9.9 Sanofi
9.10 Schott AG
9.11 Vetter Pharma-Fertigung Gmbh & Co. KG
9.12 Ypsomed Holding AG
*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies.